RANI RANI THERAPEUTICS HLDGS INC

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery 

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery 

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.

Details of the presentations are as follows:

Abstract Title: Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines

Session Type: Poster Presentation

Session Title: Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II

Session Date & Time: July 14, 2025 from 12:00 PM to 1:30 PM PT

Poster Number: MON-691

Presenting Author: Anvesh Dasari, PhD

The abstract presented at ENDO 2025 is available on the Endocrine Society . 

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.

Investor Contact:

  

Media Contact:

 



EN
14/07/2025

Underlying

RANIRANI THERAPEUTICS HLDGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RANI THERAPEUTICS HLDGS INC

 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Place...

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir ImranAt the closing of the financing, each of Samsara and Anomaly will have the right to designate one member of the Company’s board of directors SAN JOSE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-st...

October 17, 2025 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Ch...

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit royalties on product sales for the first license agreementChugai has the option to extend its rights to partner with Rani on up to 5 additional drug targets ...

October 17, 2025 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provi...

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update – Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 – – Phase 1 study for RT-114 for the treatment of obesity expected to initiate in the second half of 2025 – – Announced a warrant inducement transaction with an existing investor with gross proceeds of $4.3 m...

August 7, 2025 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Reg...

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 4,354,000 shares of Rani Therapeutics’ Class A common stock at a purchase price of $0.40 per share and pre-funded warrants to purchase ...

July 15, 2025 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics and ProGen Announce Late Breaking Presentation at EN...

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery  SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place ...

July 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch